Leveraging LAG-3: Innovative Immunotherapy Combinations for First-Line Metastatic Melanoma Treatment
Webcast
0.75 AMA PRA Category 1 Credit™ ...OVERVIEW
Leveraging LAG-3: Innovative Immunotherapy Combinations for First-Line Metastatic Melanoma Treatment is organized by Global Oncology Academy .
Publication Dates
Release Date: 04/26/2024
Expiration Date: 04/26/2025
Description:
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Describe the synergistic interaction between LAG-3 and other immune checkpoints
• Evaluate recent practice-changing data on the use of LAG-3/PD-1 combination ICI therapy in patients with metastatic melanoma
• Select appropriate evidence-based dual ICI treatment regimens for newly diagnosed patients with metastatic melanoma
• Recognize and manage treatment-related adverse events associated with the use of LAG-3/PD-1 combination ICI regimens
ACCREDITATION & CREDITS
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-038-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service at custserv@napb.net
TARGET AUDIENCE
OncologistsHematologistImmunologistsSPECIALITIES
ImmunotherapiesOncology
Quick Links